{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:33:14Z","timestamp":1791657194218,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202306220051"],"award-info":[{"award-number":["202306220051"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation \u2013 Flanders","doi-asserted-by":"crossref","award":["T003716N"],"award-info":[{"award-number":["T003716N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Fund"},{"name":"Research Council KU Leuven"},{"DOI":"10.13039\/100008953","name":"Prometheus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01639-z","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:26:14Z","timestamp":1775669174000},"page":"837-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-5989","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-2044","authenticated-orcid":false,"given":"Zhigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-4438","authenticated-orcid":false,"given":"Thierry","family":"Dervieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-1072","authenticated-orcid":false,"given":"Nick","family":"Geukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-3019","authenticated-orcid":false,"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-2930","authenticated-orcid":false,"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1639_CR1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"key":"1639_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/ibd\/izac271","volume":"29","author":"B Bokemeyer","year":"2023","unstructured":"Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, et al. Real-world comparative effectiveness of ustekinumab vs anti-TNF in Crohn\u2019s disease with propensity score adjustment: induction phase results from the prospective, observational RUN-CD study. Inflamm Bowel Dis. 2023;29:1741\u201350. https:\/\/doi.org\/10.1093\/ibd\/izac271.","journal-title":"Inflamm Bowel Dis"},{"key":"1639_CR3","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/apt.14016","volume":"45","author":"C Ma","year":"2017","unstructured":"Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232\u201343. https:\/\/doi.org\/10.1111\/apt.14016.","journal-title":"Aliment Pharmacol Ther"},{"key":"1639_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","volume":"14","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, L\u00f6wenberg M, Dijkstra G, Oldenburg B, et al. Ustekinumab for Crohn\u2019s disease: results of the ICC Registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020;14:33\u201345. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz119.","journal-title":"J Crohns Colitis"},{"key":"1639_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/apt.15958","volume":"52","author":"M Iborra","year":"2020","unstructured":"Iborra M, Beltr\u00e1n B, Fern\u00e1ndez-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2020;52:1017\u201330. https:\/\/doi.org\/10.1111\/apt.15958.","journal-title":"Aliment Pharmacol Ther"},{"key":"1639_CR6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","volume":"13","author":"C Liefferinckx","year":"2019","unstructured":"Liefferinckx C, Verstockt B, Gils A, Noman M, Van Kemseke C, Macken E, et al. Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13:1401\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz080.","journal-title":"J Crohns Colitis"},{"key":"1639_CR7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/ibd\/izab357","volume":"28","author":"M Chaparro","year":"2022","unstructured":"Chaparro M, Baston-Rey I, Fern\u00e1ndez-Salgado E, Gonz\u00e1lez Garc\u00eda J, Ramos L, Diz-Lois Palomares MT, et al. Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: the SUSTAIN Study. Inflamm Bowel Dis. 2022;28:1725\u201336. https:\/\/doi.org\/10.1093\/ibd\/izab357.","journal-title":"Inflamm Bowel Dis"},{"key":"1639_CR8","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.clinthera.2022.08.010","volume":"44","author":"OJ Adedokun","year":"2022","unstructured":"Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population pharmacokinetics and exposure\u2013response analyses of ustekinumab in patients with moderately to severely active Crohn\u2019s disease. Clin Ther. 2022;44:1336\u201355. https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.010.","journal-title":"Clin Ther"},{"key":"1639_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/jcph.1582","volume":"60","author":"Y Xu","year":"2020","unstructured":"Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z, et al. Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely ctive ulcerative colitis. J Clin Pharmacol. 2020;60:889\u2013902. https:\/\/doi.org\/10.1002\/jcph.1582.","journal-title":"J Clin Pharmacol"},{"key":"1639_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024. https:\/\/doi.org\/10.1016\/j.addr.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"key":"1639_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jcag\/gwaa003","volume":"4","author":"C Verdon","year":"2020","unstructured":"Verdon C, Vande Casteele N, Heron V, Germain P, Afif W. Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn\u2019s disease. J Can Assoc Gastroenterol. 2020;4:73\u20137. https:\/\/doi.org\/10.1093\/jcag\/gwaa003.","journal-title":"J Can Assoc Gastroenterol"},{"key":"1639_CR12","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1093\/ibd\/izz202","volume":"25","author":"WT Clarke","year":"2019","unstructured":"Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, et al. Infliximab and adalimumab concentrations may vary between the enzyme-linked immunosorbent assay and the homogeneous mobility shift assay in patients with inflammatory bowel disease: a prospective cross-sectional observational study. Inflamm Bowel Dis. 2019;25:e143\u20135. https:\/\/doi.org\/10.1093\/ibd\/izz202.","journal-title":"Inflamm Bowel Dis"},{"key":"1639_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","volume":"46","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Moes DJAR, Wang Z, Soenen R, Layegh Z, Barclay M, et al. Best practice for therapeutic drug monitoring of infliximab: position statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2024;46:291. https:\/\/doi.org\/10.1097\/FTD.0000000000001204.","journal-title":"Ther Drug Monit"},{"key":"1639_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","volume":"45","author":"K Papamichael","year":"2023","unstructured":"Papamichael K, Stocco G, Ruiz del Agua A. Challenges in therapeutic drug monitoring: optimizing biological treatments in patients with inflammatory bowel disease and other immune-mediated inflammatory diseases. Ther Drug Monit. 2023;45:579\u201390. https:\/\/doi.org\/10.1097\/FTD.0000000000001095.","journal-title":"Ther Drug Monit"},{"key":"1639_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bcp.14971","volume":"88","author":"Z Wang","year":"2022","unstructured":"Wang Z, Verstockt B, Sabino J, Vermeire S, Ferrante M, Declerck P, et al. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn\u2019s disease. Br J Clin Pharmacol. 2022;88:323\u201335. https:\/\/doi.org\/10.1111\/bcp.14971.","journal-title":"Br J Clin Pharmacol"},{"key":"1639_CR16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjz008","volume":"13","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, et al. Ustekinumab exposure-outcome analysis in Crohn\u2019s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13:864\u201372. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz008.","journal-title":"J Crohns Colitis"},{"key":"1639_CR17","doi-asserted-by":"publisher","first-page":"S439","DOI":"10.1093\/ecco-jcc\/jjx180.776","volume":"12","author":"JC Marini","year":"2018","unstructured":"Marini JC, Gils A, Shankar G, Peeters M, Brouwers E, van Iperen P, et al. P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients. J Crohn\u2019s Colitis. 2018;12:S439. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx180.776.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1639_CR18","doi-asserted-by":"publisher","first-page":"S-856","DOI":"10.1016\/S0016-5085(15)32899-7","volume":"148","author":"J Salbato","year":"2015","unstructured":"Salbato J, Westin S, Hester KD, Reddy R, Jain A, Singh S. Tu1311 validation of a homogenous mobility shift assay (HMSA) for the measurement of ustekinumab (UTK) and antibodies-to-ustekinumab (ATU) in inflammatory bowel disease (IBD) patient serum. Gastroenterology. 2015;148:S-856. https:\/\/doi.org\/10.1016\/S0016-5085(15)32899-7.","journal-title":"Gastroenterology"},{"key":"1639_CR19","unstructured":"European Medicines Agency (EMA). ICH M10 on bioanalytical method validation: scientific guideline. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline. Accessed 16 Jul 2025."},{"key":"1639_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307\u201310.","journal-title":"Lancet"},{"key":"1639_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/clinchem\/39.3.424","volume":"39","author":"K Linnet","year":"1993","unstructured":"Linnet K. Evaluation of regression procedures for methods comparison studies. Clin Chem. 1993;39:424\u201332.","journal-title":"Clin Chem"},{"key":"1639_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255\u201368.","journal-title":"Biometrics"},{"key":"1639_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1639_CR24","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentr\u00e9 F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036\u201349. https:\/\/doi.org\/10.1007\/s11095-006-9067-5.","journal-title":"Pharm Res"},{"key":"1639_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cpt.2065","volume":"109","author":"DW Uster","year":"2021","unstructured":"Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, et al. A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109:175\u201383. https:\/\/doi.org\/10.1002\/cpt.2065.","journal-title":"Clin Pharmacol Ther"},{"key":"1639_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1026","volume":"10","author":"A Chen","year":"2022","unstructured":"Chen A, Gupta A, Do DH, Nazer LH. Bayesian method application: integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring. Pharmacol Res Perspect. 2022;10:e01026. https:\/\/doi.org\/10.1002\/prp2.1026.","journal-title":"Pharmacol Res Perspect"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/psp4.12684","volume":"10","author":"JH Hughes","year":"2021","unstructured":"Hughes JH, Keizer RJ. A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacomet Syst Pharmacol. 2021;10:1150\u201360. https:\/\/doi.org\/10.1002\/psp4.12684.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1639_CR28","doi-asserted-by":"publisher","first-page":"i69","DOI":"10.1093\/ecco-jcc\/jjae190.0035","volume":"19","author":"P Bossuyt","year":"2025","unstructured":"Bossuyt P, Rahier JF, Baert F, Louis E, Macken E, Lobaton T, et al. OP35 low remission recapture after ustekinumab dose optimization in Crohn\u2019s disease: results of the randomized placebo-controlled double-blind REScUE study. J Crohns Colitis. 2025;19:i69-70. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.0035.","journal-title":"J Crohns Colitis"},{"key":"1639_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101587","volume":"13","author":"AJ Zdovc","year":"2021","unstructured":"Zdovc AJ, Han\u017eel J, Kurent T, Sever N, Ko\u017eelj M, Smrekar N, et al. Ustekinumab dosing individualization in Crohn\u2019s disease guided by a population pharmacokinetic-pharmacodynamic model. Pharmaceutics. 2021;13:1587. https:\/\/doi.org\/10.3390\/pharmaceutics13101587.","journal-title":"Pharmaceutics"},{"key":"1639_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061242","volume":"10","author":"S Restellini","year":"2021","unstructured":"Restellini S, Afif W. Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J Clin Med. 2021;10:1242. https:\/\/doi.org\/10.3390\/jcm10061242.","journal-title":"J Clin Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01639-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:06:55Z","timestamp":1781622415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01639-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01639-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thierry Dervieux is employed at Prometheus Laboratories. Nick Geukens is a co-founder and shareholder of Hemastatx, a KU Leuven spin-off company. Bram Verstockt received research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sanofi, Sossei Heptares\/Nxera, and Takeda; speaker\u2019s fees from AbbVie, Agomab, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lily, Falk, Ferring, Galapagos, Materia Prima, Johnson and Johnson, Pfizer, Sandoz, Takeda, Tillots Pharma, Truvion, and Viatris; consultancy fees from AbbVie, Agomab, Alfasigma, Alimentiv, Anaptys Bio, Applied Strategic, AstraZeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Domain Therapeutics, Eli Lily, Galapagos, Guidepont, Landos, Merck, Mirador Therapeutics, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Onco3R, Pfizer, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma, and Viatris; and stock options from Vagustim and Thetis Pharma. Marc Ferrante received research grants from AbbVie, Biogen, EG Pharma, Janssen, Pfizer, Takeda, and Viatris; consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, MRM Health, Merck Sharp and Dohme, Pfizer, Takeda, and ThermoFisher; and speakers\u2019 fees from AbbVie, Biogen, Boehringer Ingelheim, Dr Falk, Ferring, Janssen-Cilag, Merck Sharp and Dohme, Pfizer, Takeda, Truvion Healthcare, and Viatris. S\u00e9verine Vermeire received speakers\u2019 and\/or consultancy fees from AbbVie, Abivax, AbolerlsPharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Biora Therapeutics, BMS, Boehringer Ingelheim, Celgene, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech Roche, Gilead, GSK, Hospira, lmidomics, Janssen, Johnson&Johnson, Lilly, Materia Prima, Mestag Therapeutics, Microbiotica, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Surrozen, Takeda, Theravance, Tillots Pharma AG, VectivBio, Ventyx, and Zealand Pharma. S\u00e9verine Vermeire is currently the rector of KU\u00a0Leuven (2025\u201329). Erwin Dreesen received consultancy fees from Alimentiv and argenx; lecture fees from Celltrion and Galapagos; and financial support from Celltrion, Janssen, Pfizer, Prometheus, R-Biopharm, and Sandoz, with all honoraria\/fees being paid to KU\u00a0Leuven and not to any personal account of Erwin Dreesen. Wei Zhang and Zhigang Wang have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee Research (EC Research) of University Hospitals Leuven (UZ\u00a0Leuven) approved the study (S53684, S65776).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The individual participant data underlying the reported results were provided by collaborating researchers and are not publicly available because of privacy or institutional restrictions. Access to the data may be granted upon reasonable request and with permission from the original data custodians.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The NONMEM model code supporting this study is provided within the ESM.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}